Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research report report published on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Performance

NASDAQ:TRVN opened at $1.81 on Friday. The firm has a market cap of $1.56 million, a P/E ratio of -0.04 and a beta of 1.08. The stock’s 50 day simple moving average is $1.72 and its 200-day simple moving average is $2.65. Trevena has a 12-month low of $1.13 and a 12-month high of $17.50.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.